Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models

Behavioural Pharmacology
Rajkumar RamamoorthyMinasri Borah

Abstract

The present behavioural investigation evaluates the antidepressant potential of ondansetron (OND), a widely used (in management of cancer chemotherapy-induced nausea and emesis) 5-HT3 receptor antagonist. Separate groups of mice received acute or chronic treatment of OND (0.005-1000 microg/kg), and were subjected to spontaneous locomotor activity test or antidepressant assays, namely, the forced swim and tail suspension tests. Interaction studies with fluoxetine, venlafaxine, desipramine and 8-hydroxy-2-(di-n-propylamino) tetralin were conducted in the forced swim test. The effect of OND (0.01-1000 microg/kg) in combination with paroxetine (10 mg/kg, for 14 days) on the behaviour of male bulbectomized or sham-operated rats was also assessed. The postbulbectomy behavioural analysis included exploration in the open field and elevated plus maze. OND exhibited a biphasic dose-response profile, with antidepressant-like effects peaking at 0.1 microg/kg, in the forced swim and tail suspension tests. None of the tested doses influenced spontaneous locomotor activity. Chronic OND pretreatment augmented the antidepressant effects of fluoxetine and venlafaxine but did not influence the effects of desipramine or 8-hydroxy-2-(di-n-propylami...Continue Reading

References

Mar 1, 1979·Pharmacology, Biochemistry, and Behavior·K D CairncrossH Schnieden
Jul 1, 1979·Psychoneuroendocrinology·K D CairncrossA F Wren
Oct 1, 1992·Trends in Pharmacological Sciences·J A PetersJ J Lambert
Aug 7, 1992·Brain Research·A R LumiaB Possidente
Feb 25, 1992·European Journal of Pharmacology·P MartinA J Puech
May 11, 1991·Lancet·A WhiteC Faulconbridge
Jan 1, 1991·Progress in Neuro-psychopharmacology & Biological Psychiatry·M HascoëtJ Bradwejn
Dec 1, 1991·International Clinical Psychopharmacology·Y D Lapierre
Dec 1, 1991·International Clinical Psychopharmacology·J F Deakin
Jan 1, 1990·Pharmacology & Therapeutics·H van Riezen, B E Leonard
Nov 14, 1989·European Journal of Pharmacology·D HoyerM Hamon
Apr 1, 1988·British Journal of Pharmacology·B J JonesM B Tyers
Jun 1, 1987·British Journal of Pharmacology·B CostallM B Tyers
Jul 7, 1988·European Journal of Pharmacology·C WaeberJ M Palacios
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·S M Jancsàr, B E Leonard
Nov 1, 1980·Pharmacology, Biochemistry, and Behavior·C L BroekkampK G LLoyd
Jan 1, 1981·International Review of Neurobiology·B E Leonard, M Tuite
Jan 1, 1995·Neuroscience and Biobehavioral Reviews·F Borsini
Aug 1, 1995·Clinical Pharmacokinetics·F Roila, A Del Favero
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·I LuckiD S Kreiss
Mar 1, 1993·British Journal of Pharmacology·G P LuscombeD J Heal
Aug 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M BourinG B Baker
Jan 1, 1997·Depression and Anxiety·A M FreemanG Evoniuk
Jan 1, 1997·Pharmacology & Therapeutics·J P KellyB E Leonard
Mar 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C McGrath, T R Norman

❮ Previous
Next ❯

Citations

Nov 26, 2010·Psychopharmacology·Gregory V Carr, Irwin Lucki
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark J Millan
Apr 18, 2013·Asian Pacific Journal of Tropical Biomedicine·Urmila M AswarSubhash L Bodhankar
Oct 19, 2010·British Journal of Anaesthesia·V MinvilleI Tack
Sep 10, 2014·European Journal of Pharmacology·Deepali GuptaYeshwant Kurhe
Jul 14, 2010·Pharmacology & Therapeutics·Jutta WalstabBeate Niesler
Dec 8, 2009·Behavioural Brain Research·Jessica E SparlingCatherine Bielajew
Mar 16, 2016·Neuroscience and Biobehavioral Reviews·Deepali GuptaMahesh Radhakrishnan
Aug 6, 2014·European Journal of Pharmacology·Olivia F O'LearyJohn F Cryan
May 23, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alan L PehrsonConnie Sanchez
May 24, 2014·The International Journal of Neuropsychopharmacology·Ashley WallaceDavid A Morilak
Oct 24, 2012·The International Journal of Neuropsychopharmacology·Cécile BétryNasser Haddjeri
Feb 4, 2010·Journal of Psychopharmacology·Ramamoorthy Rajkumar, Radhakrishnan Mahesh
May 12, 2017·British Journal of Pharmacology·Vincent MartinLaurence Lanfumey
Dec 16, 2011·The Journal of Pharmacology and Experimental Therapeutics·A MørkT Bryan Stensbøl
Mar 3, 2020·Medicinal Research Reviews·Radomir JuzaJan Korabecny

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.